Although progress has been made in defining breast cancer subgroups and identifying patients with general chemosensitivity, we do not yet have reliable predictive markers for anthracyclines. With current evidence, neither HER-2 status nor topoisomerase IIa status can be considered clinically valuable in guiding prescription of anthracyclines.
Predicting anthracycline benefit: have we made any progress? / Moretti E; Oakman C; Di Leo A. - In: CURRENT OPINION IN ONCOLOGY. - ISSN 1040-8746. - ELETTRONICO. - (2009), pp. 507-515.
Predicting anthracycline benefit: have we made any progress?
MORETTI, ERICA;
2009
Abstract
Although progress has been made in defining breast cancer subgroups and identifying patients with general chemosensitivity, we do not yet have reliable predictive markers for anthracyclines. With current evidence, neither HER-2 status nor topoisomerase IIa status can be considered clinically valuable in guiding prescription of anthracyclines.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
